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The present article describes the synthesis of dihydrobenzo[4,5]imidazo[1,2-a]pyrimidin-4-one (2aeh)
under microwave irradiation. The product was obtained in excellent yield (74e94%) in a shorter reaction
time (2 min). These molecules (2a, b) further reacted with various substituted 4-bromomethylcoumarins
(3aef) to yield a new series of coumarin substituted dihydrobenzo[4,5]imidazo[1,2-a]pyrimidin-4-ones
(4aeh). The structure of all the synthesized compounds were conﬁrmed by spectral studies and screened
for their in vitro antibacterial activity against three Gram-positive bacteria viz., Staphylococcus aureus,
Enterococcus faecalis, Streptococcus mutans and three Gram-negative bacteria viz., Escherichia coli, Kleb-
siella pneumonia, Pseudomonas aeruginosa and antifungal activity against Candida albicans, Aspergillus
niger, Aspergillus fumigatus, Aspergillus ﬂavus, Fusarium oxysporum, Penicillium chrysogenum and anti-
cancer activity against Dalton’s Ascitic Lymphoma (DAL) cell line.
In general, all the compounds possessed better antifungal properties than antibacterial properties. The
coumarin substituted dihydrobenzo[4,5]imidazo[1,2-a]pyrimidin-4-one (4g) (R ¼ i-Pr, R1 ¼ 6-Cl) was
found to be the most potent cytotoxic compound (88%) against Dalton’s Ascitic Lymphoma cell line at the
concentration of 100 mg/mL.
 2013 Elsevier Masson SAS. All rights reserved.1. Introduction
Dihydrobenzo[4,5]imidazo[1,2-a]pyrimidin-4-one is a class of
fused tricyclic system having three nitrogen atoms. The design
concept of dihydrobenzo[4,5]imidazo[1,2-a]pyrimidin-4-ones has
arised from the broad spectrum and the wide range of biological
activities of the benzimidazole and pyrimidine.
Benzimidazole derivatives [1] exhibited high cytotoxicity
against HepG-2 cells and good EGFR inhibitory activity. 2-
Substituted-5-amino-benzimidazoles [2] possessed signiﬁcant
cytotoxicity against breast cancer cell line MCF-7. 1,2,5-
Trisubstituted benzimidazoles [3] and benzimidazolo pyrimidine
conjugates [4] were found to be antitumor agents againstvashankar).
son SAS. All rights reserved.Melanoma cell lines. QSAR analyses of 2-aminobenzimidazole de-
rivatives [5] were studied on the relation between acute toxicity
and the octanol/water partition coefﬁcient.
6-Butylfuro[2,3-d]pyrimidine derivatives [6] showed the high-
est cytostatic activity against Malignant leukemia and T-lympho-
cyte cells. 5-Benzylidine barbiturate derivatives [7] inhibited the
growth of mushroom tyrosinase and Gram-positive bacteria
Staphylococcus aureus. Pyrimidine bases [8] exerted pronounced
antiproliferative activity against the HeLa and MiaPaCa-2 cell lines.
1-Adamantyl thiopyrimidines [9] displayed the signiﬁcant cyto-
toxic activity particularly against H69AR cell line. Pyrimidine ana-
logs of indane-1,3-diones [10] showed signiﬁcant reduction
in ulcerogenic activity when compared to standard drug
Indomethacin.
The fusion of benzimidazole and pyrimidine pharmacophores in
a single molecular frame work and the study of subsequent inﬂu-
ence on the biological activities are of current interest.
Table 1
Synthesis of reported compounds (2deh) under microwave irradiation.
Compounds Thermal (reported) Microwave
Time Temperature Yield
(%)
Time Temperature Yield
(%)
2d 60 min 140 C 55 3 min 130 C 74
2e 60 min 140 C 75 3 min 130 C 87
2f 60 min 140 C 87 3 min 130 C 91
2g 60 min 140 C 80 3 min 130 C 90
2h 60 min 140 C 87 3 min 130 C 94
Synthesis of reported compounds (2deh) under microwave irradiation.
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a]pyrimidin-4-one derivatives [11] had many demerits such as long
reaction time, drastic condition, tedious experimental procedure
and low yield. Hence, there is a need for a simple and straight
forward method for the synthesis of dihydrobenzo[4,5]imidazo
[1,2-a]pyrimidin-4-one derivatives. On the otherhand, to date,
neither the synthesis nor the biological evaluation of dihydrobenzo
[4,5]imidazo[1,2-a]pyrimidin-4-ones has been reported in the
literature. For all these reasons, we have done laboratory work on
the synthesis of fused dihydrobenzo[4,5]imidazo[1,2-a]pyrimidin-
4-ones.
Coumarins are known to be biologically versatile compounds
possessing several biological properties. Coumarin Mannich bases
[12] inhibited carraggeenin-induced hind paw edema and found to
possess protective properties against adjuvant-induced arthritis in
rats. 4-Amino-3-(2-methylbenzyl)coumarin derivatives [13]
exhibited potent estrogenic activity on the estrogen receptor pos-
itive (ERþ) human MCF-7 breast cancer cell line. 4-Hydroxy
coumarin derivatives [14] showed pronounced prolongation of
prothrombin time with anticoagulant values similar to that of
warfarin. Benzothiazolyl coumarin acetamide derivatives [15]
exhibited strong in vitro anti-HIV effect against the wild-type
HIV-1 cell line. The in vitro antioxidant activities of 4-schiff bases-
7-benzyloxy coumarin derivatives [16] revealed that DPPH and
ABTSþ radical scavenging activities were better than that of the
commercial antioxidant BHT.
Based on the survey of recent literature studies on benzimid-
azoles, pyrimidines and coumarins and in our effort to discover
novel antimicrobial and anticancer agents, the aim of our work is
synthesis of coumarin substituted dihydrobenzo[4,5]imidazo[1,2-
a]pyrimidin-4-ones and to evaluate them for their therapeutic
importance.2. Chemistry
The synthesis of compounds (2aeh) (R: a; i-Pr, b; 4-CF3C6H4, c;
3-FC6H4, d; CF3, e; C6H5, f; 4-FC6H4, g; 3-ClC6H4, h; 4-CH3OC6H4)
was accomplished by synthetic sequence shown in Scheme 1. The
preparation of dihydrobenzo[4,5]imidazo[1,2-a]pyrimidin-4-ones
was carried out by the condensation of b-ketoesters (1aeh) with
2-aminobenzimidazole under microwave irradiation. The best
conditions to obtain these compounds were achieved at 130 C
using DMF as a reaction media. This method gave the higher yield
(74e94%) and required a shorter reaction time (3 min). The com-
pounds (2deh) have already been reported by the thermal method
(Table 1) in the literature [11].
4-Bromomethyl coumarins [17] (3aef) were synthesized by
Pechmann cyclization of phenols with 4-bromoethylacetoacetate
[18] using conc. H2SO4 as a cyclizing agent. The synthesis of
coumarin substituted dihydrobenzo[4,5]imidazo[1,2-a]pyrimidin-
4-ones (Scheme 2) were carried out by reaction of 4-bromomethylN
H
N
NH2 R O
O O
1a-h
R; a; i-Pr, b; 4-CF3C6H4, c; 3-FC6H4, d; CF3, e; C6
Schemecoumarins (3aef) (R1 ¼ a; 6-OMe, b; 6-F, c; 6-CH3, d; 6,8-dimethyl,
e; 6-Cl, f; 6-Br) with dihydrobenzo[4,5]imidazo[1,2-a]pyrimidin-4-
ones (2a, b) (R¼ a; i-Pr, b; 4-CF3C6H4) in the presence of anhydrous
K2CO3 in dry acetone at room temperature for 24 h. Removal of
solvents under reduced pressure afforded the title compounds
(4aeh) as solids which were puriﬁed by routine methods. The
numbering of the skeleton is shown in Fig. 1.
2.1. Result and discussion
In the IR spectrum of the compound 2-isopropyl-10H-benzo
[4,5]imidazo[1,2-a]pyrimidin-4-one (2a) (R ¼ i-Pr), the carbonyl
stretching frequencywas observed at 1664 cm1, where as the NeH
stretching frequency showed a strong absorption band at
3230 cm1. The 1H NMR spectrum of compound (2a) exhibited a
singlet in the region d 5.87 due to presence of C3eH proton. A
multiplet was observed at d 2.79 due tomethine proton of isopropyl
group. The methyl protons of isopropyl group and C7eH proton
were found to be a doublet at d 1.22 (J ¼ 9 Hz) and 8.38 (J ¼ 9 Hz)
respectively. A triplet was appeared at d 7.27 (J ¼ 6 Hz) due to the
presence of C8eH proton. The multiplet was observed in the region
between d 7.42e7.50 due to the presence of C9eH and C10eH pro-
tons. The NeH proton was resonated as a singlet at d 12.88 which
was further conﬁrmed by its D2O exchange. The mass spectrum
(ESI-MS) of the compound (2a) showed a [M þ 1] peak at 228. The
13C NMR spectral data of all the compounds is given
in Experimental section.
The IR spectrum of the compound 10-(6-methoxy-2-oxo-2H-
chromen-4-ylmethyl)-2-triﬂuoromethyl-10H-benzo[4,5]imidazo
[1,2-a]pyrimidin-4-one (4a) (R ¼ CF3 & R1 ¼ 6-OCH3) displayed the
benzimidazopyrimidine carbonyl stretching frequency at
1685 cm1, where as the lactone carbonyl stretching frequency
appeared at 1712 cm1. The 1H NMR spectrum of the compound
(4a) showed a singlet at d 3.50, 5.82, 6.02 and 6.26 due to 6-OCH3,
NeCH2, C3eH of coumarin and C3eH of benzimidazopyrimidine
protons respectively. The aromatic protons resonated as a multiplet
in the range of d 7.45e8.32. The mass spectrum (ESI-MS) of the
compound (4a) displayed a [M þ 1] peak at 442. The 13C NMR
spectral data of all the compounds is given in Experimental section.DMF
MW, 3 min N
H
N
N
O
R
2a-h
H5, f; 4-FC6H4, g; 3-ClC6H4, h; 4-OCH3C6H4
1.
N
H
N
N
O
R
O O
Anhydrous K2CO3
Dry Acetone
RT, 24 hr, Stirr
2a-b 4a-h3a-f
R1
N N
O O
N
O
R1 R
Br
Compounds 4a 4b 4c 4d 4e 4f 4g 4h
R CF3 CF3 CF3 CF3 i-Pr i-Pr i-Pr i-Pr
R1 6-OMe 6-F 6-CH3 6,8-dimethyl 6-F 6-OMe 6-Cl 6-Br
Scheme 2.
K.B. Puttaraju et al. / European Journal of Medicinal Chemistry 69 (2013) 316e322318The molecular structure of the compound (4b) is also established
by single crystal analysis [19] as shown in Fig. 2.
2.2. Antimicrobial activity
All the newly synthesized compounds (2aeh) and (4aeh) were
screened for their antibacterial and antifungal activity at different
concentrations of 100, 50, 25, 12.5, 6.25, 3.125, 1.6, 0.8, 0.4 and
0.2 mg/mL by the broth micro dilution method. The minimum
inhibitory concentrations (MIC) were determined by serial dilution
method [20].
Antibacterial activity was carried out against three Gram-
positive bacteria viz., Staphylococcus. aureus, Enterococcus faecalis,
Streptococcus mutans and three Gram-negative bacteria viz.,
Escherichia coli, Klebsiella pneumonia and Pseudomonas aeruginosa.
Ciproﬂoxacinwas used as a standard. Antifungal activity was carried
out against six fungi viz., Candida albicans, Aspergillus niger, Asper-
gillus fumigatus, Aspergillus ﬂavus, Fusarium oxysporum and Peni-
cillium chrysogenum. Fluconazole was used as a standard.
The investigation of antibacterial data (Table 2) showed that
most of the tested compounds exhibited good bacterial inhibition.
The compounds (2aeh) were found to be highly active against
E. faecalis with MIC of 0.2 mg/mL. The compound (4d) (R ¼ CF3,
R1 ¼ 6,8-dimethyl) was found to be highly active against S. mutans
with MIC of 0.2 mg/mL. The compound (4e) (R ¼ i-Pr, R1 ¼ 6-F) was
found to be most active against S. mutans with MIC of 0.8 mg/mL
(Fig. 3). It is interesting to note that all the tested compounds were
found to be most potent against E. faecalis when compared to
standard drug Ciproﬂoxacin. The rest of the compounds were found
to be inactive.
The investigation of antifungal data (Table 3) showed that most
of the tested compounds exhibited good fungal inhibition. The
compounds (2f) (R ¼ 4-FC6H4) and (2g) (R ¼ 4-ClC6H4) were foundN
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Fig. 1. Numbering of the compound (2b).to be highly active against A. fumigatus and A. ﬂavus with MIC of
0.2 mg/mL. The compounds (2b) (R ¼ 4-CF3C6H4), (2d) (R ¼ CF3),
(2e) (R ¼ C6H5), (2g) (R ¼ 3-ClC6H4), (2h) (R ¼ 4-CH3OC6H4) and
(4aeh) were found to be highly active against F. oxysporum with
MIC of 0.2 mg/mL. The compounds (2a) (R ¼ i-Pr), (2b) (R ¼ 4-
CF3C6H4), (2c) (R ¼ 3-FC6H4), (2e) (R ¼ C6H5), (4b) (R ¼ CF3,
R1 ¼ 6-F), (4c) (R ¼ CF3, R1 ¼ 6-CH3), (4d) (R ¼ CF3, R1 ¼ 6,8-
dimethyl) and (4h) (R ¼ i-Pr, R1 ¼ 6-Br) were found to be highly
active against P. chrysogenum with MIC of 0.2 mg/mL (Fig. 4). It is
interesting to note that all the tested compounds were found to be
most potent against A. fumigatus, F. oxysporum and P. chrysogenum
when compared to standard drug Fluconazole.2.3. In vitro cell cytotoxicity
The newly synthesized compounds (2aeh) and (4aeh) were
determined in vitro cell cytotoxicity by using trypan blue dye
exclusion assay method [21]. In this test, only the dead cells took up
the dye due to lack of intact membranes. Dalton’s Ascitic Lym-
phoma (DAL) cells (0.2 mL, 106 cells/mL), ice cold phosphate buffer
saline (1 mL, pH ¼ 7.4) and one of the compounds (2aeh) and (4ae
h) (0.2 mL) were taken in an Eppendorf tube. They were incubated
in CO2 incubator at 37 C with continuous ﬂow of 5% CO2 for 3 h.Fig. 2. ORTEP diagram with the displacement at 50% probability level (4b).
Table 2
Results of antibacterial activities of compounds 2aeh and 4aeh MICs (mg/mL).
Compounds Gram-positive Gram-negative
S. aureus E. faecalis S. mutans E. coli K. penumoniae P. aeruginosa
2a 100 0.2 25 12.5 100 12.5
2b >100 0.2 >100 >100 >100 >100
2c 100 0.2 12.5 100 100 25
2d 100 0.2 50 100 100 100
2e 100 0.2 100 100 100 100
2f 100 0.2 12.5 100 100 100
2g 100 0.2 25 100 100 100
2h 100 0.2 100 100 100 100
4a 100 0.4 12.5 100 100 >100
4b 100 0.8 12.5 100 100 100
4c 100 0.4 12.5 100 100 >100
4d 100 0.4 0.2 100 100 100
4e 100 0.4 0.8 100 100 100
4f 100 0.4 3.16 100 100 >100
4g 100 0.4 12.5 100 100 100
4h >100 0.8 >100 100 >100 >100
Ciproﬂoxacin 2 2 2 1 1 2
K.B. Puttaraju et al. / European Journal of Medicinal Chemistry 69 (2013) 316e322 319Then, previous mixture (0.2 mL), ice cold phosphate buffer saline
(0.3 mL, pH ¼ 7.4) and trypan blue solution (0.5 mL, 0.4% in normal
saline) were taken in an Eppendorf tube and kept for 5e15 min at
room temperature. The percentage of dead cells was calculated
with the following formula using Neubauer chamber.
% Dead cell ¼ Number of dead cells
Sum of dead cells and living cells
 100
The investigation of in vitro cell cytotoxicity (Table 4) revealed
that most of the tested compounds exhibited good activity. The
compounds (2b) (R ¼ 4-CF3C6H4), (2d) (R ¼ CF3), (2fb) (R ¼ 4-
FC6H4), (2g) (R ¼ 4-ClC6H4), (4b) (R ¼ CF3, R1 ¼ 6-F), (4d)
(R¼ CF3, R1¼6,8-dimethyl), (4e) (R¼ i-Pr, R1¼6-F) and (4g) (R¼ i-
Pr, R1¼6-Cl) were found to be highly active (>70%) against DAL cell
at the concentration of 100 mg/mL. The rest of the compounds were
found to be moderately active (>40%) against DAL cell at the con-
centration of 100 mg/mL (Fig. 5).
3. Experimental section
The melting points were determined by open capillary method
using electric melting point apparatus and are uncorrected. The IR0.125
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Fig. 3. Antibacterial activity of comspectra (KBr disc) were recorded on a Shimadzu-8400S FT-IR
Spectrophotometer. 1H NMR spectra were recorded on Bruker
300 MHz spectrometer. 13C NMR, HeH Cosy, HSQC and 19F NMR
spectra were recorded on Bruker 400 MHz spectrometer by using
DMSO-d6 as a solvent and TMS as an internal standard. The
chemical shifts are expressed in d ppm. The mass spectra were
recorded using Agilent-Single Quartz ESI-MS and Agilent-Single
Quartz LC-MS. The purity of the compounds was checked by TLC.
Milestone laboratory’s microwave reactor was used to carry out the
microwave reactions. The elemental analyses were carried out us-
ing Elemental Vario Micro Cube CHN Rapid Analyzer. All the com-
pounds gave satisfactory elemental analysis.3.1. General procedure for the preparation of compounds
3.1.1. Synthesis of 10H-benzo[4,5]imidazo[1,2-a]pyrimidin-4-ones
(2aeh)
An equimolar mixture of 2-aminobenzimadzole (0.5 g,
3.75 mmol) and b-ketoesters (1aeh) (3.75 mmol) in DMF (10 mL)
was added to a microwave tube equipped with a magnetic stir bar.
The microwave tube was ﬁtted with a reﬂux condenser and irra-
diated in a microwave reactor at a temperature of 130 C for 3 minS.aureus
E.faecalis
S.mutans
E.coli
K.penumoniae
P.aeruginosa
pounds (2aeh) and (4aeh).
Table 3
Results of antifungal activities of compounds (2aeh) and (4aeh) MICs (mg/mL).
Compounds C. albicans A. niger A. fumigatus A. ﬂavus F. oxysporum P. chrysogenum
2a 3.12 25 1.6 1.6 0.4 0.2
2b 6.25 100 1.6 1.6 0.2 0.2
2c 1.6 12.5 0.8 0.8 0.4 0.2
2d 1.6 6.25 0.8 0.8 0.2 0.4
2e 1.6 6.25 0.8 0.8 0.2 0.2
2f 1.6 1.6 0.2 0.2 0.4 0.4
2g 1.6 25 0.2 0.2 0.2 0.4
2h 6.25 25 1.6 0.8 0.2 0.4
4a 50 25 6.25 3.12 0.2 0.4
4b 50 25 1.6 1.6 0.2 0.2
4c 50 12.5 25 12.5 0.2 0.2
4d 50 3.12 1.6 3.12 0.2 0.2
4e 25 1.6 0.8 1.6 0.2 0.4
4f 25 50 0.8 0.8 0.2 0.8
4g 50 12.5 0.8 1.6 0.2 0.4
4h 50 25 0.8 0.8 0.2 0.2
Fluconazole 16 8 8 8 8 8
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poured on to crushed ice. The solid was ﬁltered and washed with
100 mL of cold water. The crude product was dried and recrystal-
lized from 1:3 ethyl acetate and chloroform.
3.1.1.1. 2-Isopropyl-10H-benzo[4,5]imidazo[1,2-a]pyrimidin-4-one
(2a). Colorless solid, Yield: 93%. Mp: 189e191 C, IR (KBr, cm1):
3230 cm1 (NeH), 1664 cm1 (C]O); 1H NMR (300 MHz, DMSO-
d6): d 1.22 (d, 6H, 2-CH3 of i-Pr, J ¼ 6.9 Hz), 2.79 (m, 1H, CH of i-Pr),
5.87 (s, 1H, C3eH), 7.27 (t, 1H, C8eH, J ¼ 7.8 Hz), 7.42e7.50 (m, 2H,
C9eH & C10eH), 8.38 (d, 1H, C7eH, J ¼ 8.1 Hz), 12.88 (s, 1H, NeH,
D2O exchangeable) ppm; 13C NMR (100 MHz, DMSO-d6): d 21.65,
34.87, 98.42, 113.59, 115.08, 121.28, 125.92, 126.81, 135.16, 148.25,
158.95, 159.22 ppm; ESI-MS: m/z [M þ 1] 228; Anal. C13H13N3O.
Calcd for: C, 68.70; H, 5.77; N, 18.49. Found: C, 68.60; H, 5.71; N,
18.37.
3.1.1.2. 2-(4-Triﬂuoromethyl-phenyl)-10H-benzo[4,5]imidazo[1,2-a]
pyrimidin-4-one (2b). Colorless solid, Yield: 87%. Mp: 233e235 C,
IR (KBr, cm1): 3236 cm1 (NeH), 1687 cm1 (C]O); 1H NMR
(300 MHz, DMSO-d6): d 6.82 (s, 1H, C3eH), 7.34e7.39 (m, 1H, C10e
H), 7.51e7.53 (d, 2H, C8eH & C9eH, J ¼ 3.9 Hz), 8.05 (d, 2H, C15eH &
C19eH, J ¼ 6.0 Hz), 8.48 (d, 1H, C7eH, J ¼ 8.1 Hz), 8.73 (d, 2H, C16eH
& C18eH, J ¼ 3.6 Hz), 13.14 (s, 1H, NeH) ppm; 13C NMR (100 MHz,0.125
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Fig. 4. Antifungal activity of comDMSO-d6): 98.18, 111.02, 115.69, 117.46, 120.56, 121.93, 125.45,
126.30, 126.92, 127.71, 129.12, 129.89 (q, 2JCF ¼ 32 Hz), 140.99,
148.14, 149.54, 158.93, 166.44 ppm; ESI-MS:m/z [M þ 1] 330; Anal.
C17H10 F3N3O. Calcd for: C, 62.01; H, 3.06; N, 12.76. Found: C, 61.92;
H, 2.91; N, 12.60.
3.1.1.3. 2-(3-Fluoro-phenyl)-10H-benzo[4,5]imidazo[1,2-a]pyr-
imidin-4-one (2c). Colorless solid, Yield: 94%. Mp: 213e215 C, IR
(KBr, cm1); 3237 cm1 (NeH), 1681 cm1 (C]O); 1H NMR
(300 MHz, DMSO-d6) d 6.65 (s, 1H, C3eH), 7.31e7.38 (m, 3H, AreH),
7.49 (d, 2H, J ¼ 3.9 Hz), 8.17e8.21 (m, 2H, AreH), 8.46 (d, 1H,
J ¼ 8.1 Hz, AreH), 13.11 (s, 1H, NeH) ppm; 13C NMR (100 MHz,
DMSO-d6): d 97.62, 110.97, 113.42, (d, 2JCF ¼ 23 Hz), 115.67, 116.81,
121.89, 123.0, 125.69, 126.25, 130.47, 130.58, 139.56, 139.64, 149.46,
159.06, 159.71, 161.20, 163.61 ppm; ESI-MS: m/z [M þ 1] 280; Anal.
C16H10FN3O. Calcd for: C, 68.81; H, 3.61; N, 15.05. Found: C, 68.70;
H, 3.55; N, 14.97.
3.1.2. Synthesis of 10-(2-oxo-2H-chromen-4-ylmethyl-10H-benzo
[4,5]imidazo[1,2-a])pyrimidin-4-ones (4aeh)
A mixture of 10H-benzo[4,5]imidazo[1,2-a]pyrimidin-4-ones
(2a, b) (2.20 mmol) and anhydrous K2CO3 (0.6 g, 4.4 mmol) was
stirred in 30 mL of dry acetone for 20 min. 4-
Bromomethylcoumarins (3aef) (2.20 mmol) was added andC.Albican
A.niger
A.fumigatus
A.flaves
F.oxysporum
P.chrysogenum
Flu
con
ozo
le
pounds (2aeh) and (4aeh).
Table 4
In vitro cytotoxicity of compounds (2aeh) and (4aeh).
Type of cancer
cell (1  105)
Concentration of
compounds
(mg/ml)
Number of
compounds
Number of
cells
% of dead
cells
Live Dead
Dalton’s Ascitic
Lymphoma
100 2a 43 57 57
100 2b 21 79 79
100 2c 46 54 54
100 2d 20 80 80
100 2e 42 58 58
100 2f 17 83 83
100 2g 29 71 71
100 2h 36 64 64
100 4a 42 58 58
100 4b 21 79 79
100 4c 31 69 69
100 4d 22 78 78
100 4e 19 81 81
100 4f 38 62 62
100 4g 12 88 88
100 4h 53 47 47
5-Flourouracil 100 e 12 88 88
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concentrated to one fourth volume and poured on to crushed ice.
The solid separated was ﬁltered and washed with 5% HCl (10 mL).
Then, it was washed with 50 mL of cold water. The crude product
was dried and recrystallized from ethanol.
3.1.2.1. 10-(6-Methoxy-2-oxo-2H-chromen-4-ylmethyl)-2-triﬂuoro-
methyl-10H-benzo[4,5] imidazo[1,2-a]pyrimidin-4-one (4a).
Colorless solid, Yield: 93%. Mp: 228e230 C, IR (KBr, cm1):
1685 cm1 (C]O), 1712 cm1 (lactone C]O); 1H NMR (300 MHz,
DMSO-d6): d 3.50 (s, 3H, OCH3), 5.82 (s, 2H, NeCH2), 6.02 (s,1H, C3e
H of coumarin), 6.26 (s,1H, C3eH of benzimidazopyrimidine), 7.45e
8.32 (m, 7H, AreH) ppm; 13C NMR (100 MHz, DMSO-d6) d 42.64,
55.86, 100.84, 107.75, 100.52, 112.32, 116.02, 117.56, 117.70, 119.87,
123.36, 125.36, 126.84, 130.74, 147.37, 148.48, 149.41 (q,
2JCF ¼ 64 Hz), 150.05, 155.64, 158.96, 159.57 ppm; ESI-MS: m/z
[M þ 1] 442; Anal. C22H14F3N3O4. Calcd for: C, 59.87; H, 3.20; N,
9.52. Found: C, 59.68; H, 3.06; N, 9.30.
3.1.2.2. 10-(6-Fluoro-2-oxo-2H-chromen-4-ylmethyl)-2-triﬂuoro-
methyl-10H-benzo[4,5]imidazo [1,2-a]pyrimidin-4-one (4b).
Colorless solid, Yield: 90%. Mp: 240e245 C, IR (KBr, cm1):0
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Fig. 5. In vitro cell cytotoxicit1673 cm1 (C]O), 1738 cm1 (lactone C]O); 1H NMR (300 MHz,
DMSO-d6): d 5.86 (s, 2H, NeCH2), 6.28 (s, 1H, C3eH of coumarin),
6.64 (s, 1H, C3eH of benzimidazopyrimidine), 7.47e8.58 (m, 7H,
AreH); 13C NMR (100 MHz, DMSO-d6): d 42.44, 100.88, 110.54,
111.44, 113.12, 116.01, 118.16, 118.46, 118.55, 119.49, 119.74, 123.38,
125.39, 126.83, 130.71, 148.15, 149.44, 150.03 (q, 2JCF ¼ 34 Hz),
156.91, 158.96, 159.23, 159.30 ppm; ESI-MS: m/z [M þ 1] 430; Anal.
C21H11F4N3O3. Calcd for: C, 58.75; H, 2.58; N, 9.79. Found: C, 58.63;
H, 2.47; N, 9.56.
3.1.2.3. 10-(6-Methyl-2-oxo-2H-chromen-4-ylmethyl)-2-triﬂuoro-
methyl-10H-benzo[4,5]Imidazo [1,2-a]pyrimidin-4-one (4c).
Colorless solid, Yield: 92%. Mp: 211e213 C, IR (KBr, cm1):
1665 cm1 (C]O), 1734 cm1 (lactone C]O); 1H NMR (300 MHz,
DMSO-d6): d 2.45 (s, 3H, CH3), 5.86 (s, 2H, NeCH2), 6.15 (s, 1H, C3eH
of coumarin), 6.64 (s, 1H, C3eH of benzimidazopyrimidine), 7.37e
8.58 (m, 7H, AreH) ppm; 13C NMR (100 MHz, DMSO-d6): d 20.31,
42.63, 100.81, 110.23, 111.70, 115.73, 116.63, 119.74, 121.15, 122.32,
123.34, 125.17, 125.32, 125.56, 127.16, 130.81, 133.18, 134.38, 148.81,
150.04 (q, 2JCF¼ 34 Hz),158.93 ppm; ESI-MS:m/z [Mþ 1] 426; Anal.
C23H16F3N3O3. Calcd for: C, 62.12; H, 3.32; N, 9.88. Found: C, 62.01;
H, 3.21; N, 9.74.
3.1.2.4. 10-(6,8-Dimethyl-2-oxo-2H-chromen-4-ylmethyl)-2-
triﬂuoromethyl-10H-benzo[4,5] imidazo[1,2-a]pyrimidin-4-one (4d).
Colorless solid, Yield: 91%. Mp: 216e218 C, IR (KBr, cm1):
1670 cm1 (C]O), 1730 cm1 (lactone C]O); 1H NMR (300 MHz,
DMSO-d6): d 2.36 (s, 3H, 6-CH3), 2.41 (s, 3H, 8-CH3), 5.84 (s, 2H, Ne
CH2), 6.13 (s, 1H, C3eH of coumarin), 6.64 (s, 1H, C3eH of benzi-
midazopyrimidine), 7.43e8.58 (m, 6H, AreH) ppm; 13C NMR
(100 MHz, DMSO-d6): d 15.16, 20.30, 42.62, 100.08, 110.52, 111.69,
115.98, 116.62, 122.46, 122.31, 123.33, 125.16, 125.31, 126.86, 130.80,
133.17, 134.37, 148.79, 149.35, 149.46, 150.03 (q, 2JCF ¼ 35 Hz),
158.92, 159.53 ppm; ESI-MS: m/z [M þ 1] 440; Anal. C23H16F3N3O3.
Calcd For: C, 62.87; H, 3.67; N, 9.56. Found: C, 62.67; H, 3.58; N,
9.40.
3.1.2.5. 10-(6-Fluoro-2-oxo-2H-chromen-4-ylmethyl)-2-isopropyl-
10H-benzo[4,5]imidazo[1,2-a] pyrimidin-4-one (4e). Colorless solid,
Yield: 88%. Mp: 230e232 C, IR (KBr, cm1): 1664 cm1 (C]O),
1736 cm1 (lactone C]O); 1H NMR (300 MHz, DMSO-d6): d 1.20 (d,
6H, 2CH3 of i-Pr, J ¼ 6.0 Hz), 2.80 (m, 1H, CH of i-Pr), 5.82 (s, 2H, Ne
CH2), 6.03 (s, 1H, C3eH of coumarin), 6.24 (s, 1H, C3eH of benzi-
midazopyrimidine), 7.45e8.50 (m, 7H, AreH) ppm; 13C NMRy of (2aeh) and (4aeh).
K.B. Puttaraju et al. / European Journal of Medicinal Chemistry 69 (2013) 316e322322(100 MHz, DMSO-d6): d 21.77, 33.95, 42.98, 96.88, 101.97, 110.54,
112.88, 116.92, 117.76, 121.47, 122.76, 123.85, 125.91, 128.52, 131.27,
132.69, 142.60, 144.96, 145.10, 152.93 (d, 2JCF ¼ 66 Hz), 153.66,
161.23 ppm; LC-MS:m/z [Mþ 1] 404; Anal. C23H18FN3O3. Calcd for:
C, 68.48; H, 4.50; N, 10.42. Found: C, 68.34; H, 4.40; N, 10.29.
3.1.2.6. 10-(6-Methoxy-2-oxo-2H-chromen-4-ylmethyl)-2-isopropyl-
10H-benzo[4,5]imidazo[1,2-a] pyrimidin-4-one (4f). Colorless solid,
Yield: 94%. Mp: 210e213 C, IR (KBr, cm1): 1670 cm1 (C]O),
1740 cm1 (lactone C]O); 1H NMR (300 MHz, DMSO-d6): d 1.20 (d,
6H, 2-CH3 of i-Pr, J ¼ 6.0 Hz), 2.80 (m, 1H, CH of i-Pr), 3.52 (s, 3H,
OCH3), 5.82 (s, 2H, NeCH2), 6.01 (s, 1H, C3eH of coumarin), 6.10 (s,
1H, C3eH of benzimidazopyrimidine), 7.25e8.52 (m, 7H, AreH)
ppm; 13C NMR (100 MHz, DMSO-d6): d 23.90, 32.27, 42.37, 55.85,
101.49, 110.01, 112.38, 114.46, 115.06, 115.67, 116.20, 117.42, 117.73,
119.86, 122.49, 122.60, 126.01, 130.59, 147.39, 149.04, 155.65, 159.52,
163.87 ppm; ESI-MS:m/z [M þ 1] 416; Anal. C24H21N3O4. Calcd for:
C, 69.39; H, 5.10; N, 10.11. Found: C, 69.17; H, 4.86; N, 10.01.
3.1.2.7. 10-(6-Chloro-2-oxo-2H-chromen-4-ylmethyl)-2-isopropyl-
10H-benzo[4,5]imidazo[1,2-a] pyrimidin-4-one (4g). Colorless solid,
Yield: 89%. Mp: 237e239 C, IR (KBr, cm1): 1669 cm1 (C]O),
1732 cm1 (lactone C]O): 1H NMR (300 MHz, DMSO-d6): d 1.20 (d,
6H, 2CH3 of i-Pr, J ¼ 6.0 Hz), 2.78 (m, 1H, CH of i-Pr), 5.82 (s, 2H, Ne
CH2), 6.03 (s, 1H, C3eH of coumarin), 6.26 (s, 1H, C3eH of benzi-
midazopyrimidine), 7.39e8.51 (m, 7H, AreH) ppm; 13C NMR
(100 MHz, DMSO-d6): d 20.34, 33.33, 42.53, 100.81, 110.56, 111.98,
115.99, 116.39, 116.87, 123.35, 124.80, 125.34, 126.87, 130.83, 133.21,
133.85, 142.81, 148.61, 151.15, 153.36, 158.96 ppm; ESI-MS: m/z
[M þ 2] 421; Anal. C23H18ClN3O3. Calcd for: C, 65.79; H, 4.32; N,
10.01. Found: C, 65.65; H, 4.16; N, 9.86.
3.1.2.8. 10-(6-Bromo-2-oxo-2H-chromen-4-ylmethyl)-2-isopropyl-
10H-benzo[4,5]imidazo[1,2-a] pyrimidin-4-one (4h). Colorless solid,
Yield: 95%. Mp: 213e215 C, IR (KBr, cm1): 1672 cm1 (C]O),
1731 cm1 (lactone C]O); 1H NMR (300 MHz, DMSO-d6): d 1.24 (d,
6H, 2CH3 of i-Pr, J ¼ 6.0 Hz), 2.73 (m, 1H, CH of i-Pr), 5.80 (s, 2H, Ne
CH2), 6.03 (s, 1H, C3eH of coumarin), 6.34 (s, 1H, C3eH of benzi-
midazopyrimidine), 7.32e8.55 (m, 7H, AreH) ppm; 13C NMR
(100 MHz, DMSO-d6): d 21.64, 34.87, 40.13, 98.44, 113.60, 115.08,
116.21, 116.85, 118.83, 119.08, 121.30, 125.44, 126.79, 127.73, 134.80,
135.10, 148.22, 150.07, 152.53, 159.04, 159.20 ppm; ESI-MS: m/z
[M þ 2] 466; Anal. C23H18BrN3O3. Calcd for: C, 59.50; H, 3.91; N,
9.05. Found: C, 59.38; H, 3.79; N, 8.91.
4. Conclusion
In conclusions, we have developed a simple method for the
synthesis of dihydrobenzo[4,5]imidazo[1,2-a]pyrimidin-4-ones un-
der microwave irradiation giving excellent yields of the products
(74e94%) in shorter reaction time (3 min). These molecules further
reacted with various substituted 4-bromomethylcoumarins to yield
a new series of coumarin substituted dihydrobenzo[4,5]imidazo
[1,2-a]pyrimidin-4-ones. The in vitro antimicrobial screening
revealed that all the tested compounds possessed better antifungalproperties than antibacterial properties. The coumarin substituted
dihydrobenzo[4,5]imidazo[1,2-a]pyrimidin-4-one (4g) (R ¼ i-Pr,
R1 ¼ 6-Cl) was found to be the most potent cytotoxic compound
(88%) against Dalton’s Ascitic Lymphoma cell line at the concentra-
tion of 100 mg/mL.
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